One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy
Abstract Background Central serous chorioretinopathy (CSC) is characterized by an accumulation of subretinal fluid (SRF) in the macula. It is usually treated by laser photocoagulation or photodynamic therapy (PDT) with consisting of different doses and power. This study aimed to compare the efficacy...
Main Authors: | Jirarattanasopa Pichai, Banchasakjaroen Vanchalerm, Ratanasukon Mansing |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12886-020-01796-0 |
Similar Items
-
Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
by: Alp Atik, et al.
Published: (2017-08-01) -
Comparison between the functional and anatomical outcomes of full-dose, half-dose photodynamic therapy and intravitreal bevacizumab in chronic central serous chorioretinopathy
by: Abdelrahman G Salman
Published: (2015-01-01) -
Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
by: Dhirani NA, et al.
Published: (2017-12-01) -
High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
by: Ratanasukon Mansing, et al.
Published: (2012-07-01) -
Derivatives of Natural Chlorophylls as Agents for Antimicrobial Photodynamic Therapy
by: Nikita Suvorov, et al.
Published: (2021-06-01)